<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284177</url>
  </required_header>
  <id_info>
    <org_study_id>334-103-00001</org_study_id>
    <nct_id>NCT03284177</nct_id>
  </id_info>
  <brief_title>A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients</brief_title>
  <official_title>A Multicenter, Open-label Trial to Investigate the Safety of C13-CAC and the Relationship Among C13-CAC Breath Test, Gastric pH, and the Improvement of Symptoms in PPI Resistant GERD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety of C13-CAC and the relationship among C13-CAC breath test, gastric
      pH, and the improvement of symptoms by switching PPI in PPI resistant GERD patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>13CO2 concentration in expired air.</measure>
    <time_frame>5，10，15，20，25 and 30 minutes after C13-CAC administration.</time_frame>
    <description>Sensitivity and specificity of 13CO2 concentration in expired air for improvement of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric pH</measure>
    <time_frame>1 hour prior to C13-CAC administration</time_frame>
    <description>Sensitivity and specificity of mean gastric pH for improvement of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>C13-CAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium (13C)Carbonate</intervention_name>
    <description>Breath test of Calcium (13C)Carbonate on Visit 1 and Visit 3 under fasting conditions.</description>
    <arm_group_label>C13-CAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gastric acid inhibitors</intervention_name>
    <description>Another gastric acid inhibitor will be orally administered once daily for 4 weeks after visit 1</description>
    <arm_group_label>C13-CAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GERD patients who have been judged to require additional treatment to improve their
             symptoms by investigator or subinvestigator.

        Exclusion Criteria:

          -  Patients suspected to have hypothyroidism or hyperparathyroidism.

          -  Patients with hypercalcemia

          -  Patients with a history of gastric or duodenal surgery.

          -  Patients who have received the eradication therapy of Helicobacter pylori within six
             months prior to participation of the study.

          -  Patients with a prior or current history of Zollinger-Ellison syndrome.

          -  Patients with a history of surgery or treatment affecting gastroesophageal reflux.

          -  Patients who have been diagnosed with acute upper gastrointestinal bleeding or active
             gastric or duodenal ulcer within 30 days prior to participation of the study.

          -  Patients with serious central nervous system disorders, cardiovascular disease,
             pulmonary disease, hepatic disease, renal disease, metabolic disease, gastrointestinal
             disorders, urinary disorders, endocrine disease, or blood dyspraxia.

          -  Patients scheduled for surgery requiring hospitalization or required surgery during
             the study period.

          -  Patients who have had either a prior or current history of chest pain due to heart
             disease or with chest pain suspected to have caused by heart disease within one year
             prior to participation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kimiyoshi Sudoh, Director</last_name>
    <phone>+81-3-6361-7312</phone>
    <email>sudokun@otsuka.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kansai</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

